NeuroBo completes SAD Part 1 enrollment for obesity drug DA-1726; no issues, top-line data Q3 2024

MetaVia Inc.

45 participants enrolled across 5 cohorts in SAD Part 1 of Phase 1 trial for DA-1726 (GLP1R/GCGR dual agonist).
No significant issues; accelerated start to MAD Part 2 dosing began June 2024.
Top-line SAD data expected Q3 2024; MAD top-line data Q1 2025.
Pre-clinical data showed superior weight loss vs semaglutide and survodutide, comparable to tirzepatide.
Part 3 IND update planned; first patient dosing Q3 2025, interim data mid-2026, top-line H2 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.